MG1141A as a Highly Potent Monoclonal Neutralizing Antibody Against SARS-CoV-2 Variants

MG1141A as a Highly Potent Monoclonal Neutralizing Antibody Against SARS-CoV-2 Variants

Since the coronavirus disease outbreak in 2019, several antibody therapeutics have been developed to treat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections. Antibody therapeutics are effective in neutralizing the virus and reducing hospitalization in patients with mild and mod...

Full description

Bibliographic Details
Main Authors: Sua Lee, Shina Jang, Jihoon Kang, Soo Bin Park, Young Woo Han, Hyemi Nam, Munkyung Kim, Jeewon Lee, Ki Joon Cho, Jeonghun Kim, Miyoung Oh, Jihye Ryu, Jong Hyeon Seok, Yunhwa Kim, Jee-Boong Lee, Man-Seong Park, Yong-Sung Kim, Hosun Park, Dong-Sik Kim
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-11-01
Series:Frontiers in Immunology
Subjects:
MG1141A
SARS-CoV-2
monoclonal antibody
outbreak
spike protein
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2021.778829/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2021.778829/full

Similar Items